Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug

Scand J Gastroenterol. 1992;27(3):175-83. doi: 10.3109/00365529208999945.


Maintenance treatment with cisapride was evaluated in 298 patients in whom reflux oesophagitis had been healed with antisecretory drugs. Initially, 34% of the patients had grade-I oesophagitis, 33% had grade II, and 33% had grade III. The patients were treated with 20 mg cisapride twice daily or placebo for 6 months or until endoscopic relapse was shown if this occurred earlier. Survival analysis showed that cisapride significantly prolonged the time to endoscopic relapse in grade-I patients (P = 0.02). The intergroup difference in symptomatic relapse in all patients was also significant (P = 0.010). The effect of cisapride was less clearcut in grade II or III, and/or in patients healed with omeprazole. Factors associated with early relapse were placebo therapy, prior omeprazole therapy, duration of pre-trial symptomatic period, and initial endoscopic severity grade. Adverse experiences were limited; diarrhoea was reported by 9% of the cisapride patients.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Ulcer Agents / therapeutic use*
  • Cisapride
  • Double-Blind Method
  • Esophagitis, Peptic / drug therapy*
  • Esophagitis, Peptic / epidemiology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Omeprazole / therapeutic use
  • Piperidines / therapeutic use*
  • Recurrence
  • Serotonin Antagonists / therapeutic use*
  • Survival Analysis


  • Anti-Ulcer Agents
  • Piperidines
  • Serotonin Antagonists
  • Omeprazole
  • Cisapride